Taken together, our results from the HuPD-H1 model show that expansion of the CX3CR1+CD8+ T cell subset can be induced by the presence of ICB therapy at the time of T cell priming, and an increase in these cells is correlated with enhanced tumor rejection in the anti–PD-1/L1-treated mice. This evidence concerns the gene CD8A and neoplasm.